Eisai Co., Ltd. and Biogen Inc. announced on January 6th that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb, which has the brand name in the United States of LEQEMBITM, for the treatment of Alzheimer’s disease. The approval is based on Phase 2 data that demonstrated that LEQEMBI reduced the accumulation of Aβ plaque in the brain, a defining feature of Alzheimer’s disease. Newt’s guest is Dr. Marwan Sabbagh, MD. He is a behavioral neurologist in the Alzheimer’s and Memory Disorders Program and a professor in the Department of Neurology at Barrow Neurological Institute and was one of the leading doctors of the study.
See omnystudio.com/listener for privacy information.
Episode 696: The New Space Race – United States vs. China
Episode 695: Nuclear War: A Scenario
Episode 694: Defeating Hamas in Rafah
Episode 693: Emperor Penguin Chicks Jump Off a 50 Foot Ice Shelf
Episode 692: Governor Reagan on College Protests
Episode 691: The Power of A.I. – An Overview
Episode 690: Wall Street’s War on Workers
Episode 689: Family Unfriendly
Episode 688: Artificial Intelligence Policy
Episode 687: Reforming the Criminal Justice System
Episode 686: Iran Attacks Israel
Episode 685: Welfare Reform
Episode 684: Funding the War in Ukraine
Episode 683: Student Loan Debt Forgiveness
Episode 682: Ukraine’s War of Independence
Episode 681: How Happy Are We?
Episode 680: Pigs in the Swamp – Earmarks in the $1.2 Trillion Spending Bill
Episode 679: Lincoln, Democracy, and The American Experiment
Episode 678: Newt Answers Your Questions
Episode 677: Men Without Meaning
Create your
podcast in
minutes
It is Free